ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahmani, Nora E., Ramachandra, Nandini, Sahu, Srabani, Gitego, Nadege, Lopez, Andrea, Pradhan, Kith, Bhagat, Tushar D., Gordon-Mitchell, Shanisha, Pena, Bianca Rivera, Kazemi, Mohammad, Rao, Keshav, Giricz, Orsi, Maqbool, Shahina Bano, Olea, Raul, Zhao, Yongmei, Zhang, Jinghang, Dolatshad, Hamid, Tittrea, Vickram, Tatwavedi, Dharamveer, Singh, Shalini, Lee, Juseong, Sun, Tianyu, Steidl, Ulrich, Shastri, Aditi, Inoue, Daichi, Abdel-Wahab, Omar, Pellagatti, Andrea, Gavathiotis, Evripidis, Boultwood, Jacqueline, Verma, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455571/
https://www.ncbi.nlm.nih.gov/pubmed/34548471
http://dx.doi.org/10.1038/s41408-021-00541-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455571/
https://www.ncbi.nlm.nih.gov/pubmed/34548471
http://dx.doi.org/10.1038/s41408-021-00541-0

Ejemplares similares